What is the current Single-cell Omics market size?

The Single-cell Omics market size was valued at USD 1.2 billion in 2023, driven by advancements in sequencing technologies and rising demand for precision medicine.

What is the expected growth rate for the Single-cell Omics market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by innovations in single-cell sequencing and expanding applications in oncology and immunology.

What are the key drivers of the Single-cell Omics market?

Key drivers include the rise in personalized medicine, increasing R&D investments in biopharma, and advancements in high-throughput single-cell sequencing technologies.

What challenges does the Single-cell Omics market face?

High costs of equipment and reagents, complex data analysis, and limited skilled professionals hinder market adoption despite its potential.

Which regions are leading in the Single-cell Omics market?

North America leads the market due to robust R&D infrastructure, followed by Europe, driven by precision medicine initiatives and strong government funding.

Who are the top companies in the Single-cell Omics market?

Leading players include 10x Genomics, Illumina, Thermo Fisher Scientific, and Becton Dickinson, focusing on product innovation and strategic partnerships.

What future opportunities exist in the Single-cell Omics market?

Opportunities lie in expanding applications in cell therapy development, infectious disease research, and single-cell spatial profiling for drug discovery.

How is technology impacting the Single-cell Omics market?

Advances in AI-driven data analytics, microfluidics, and automation are enhancing throughput and accuracy, enabling broader clinical and research adoption.

What is the regulatory landscape for Single-cell Omics?

Regulatory bodies like FDA and EMA are developing frameworks to standardize single-cell techniques, ensuring quality and reproducibility for clinical diagnostics.

Why Is the Single-cell Omics Market Growing So Fast? 2026 Analysis

Single-cell Omics by Application (Pharmaceutical & Biotechnology Companies, Academic and Research Organizations, Hospital and Diagnostic Laboratories, Others), by Types (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, Single-Cell Metabolomics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Single-cell Omics Market Size | CAGR 18.5 Forecast 2033

Why Is the Single-cell Omics Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Single-cell Omics Market Overview

Single-cell Omics refers to the analysis of biological processes at the single-cell level, enabling unprecedented insights into cellular heterogeneity, disease mechanisms, and therapeutic responses. This market is poised for transformative industry expansion, driven by advancements in next-generation sequencing (NGS), AI-driven data analytics, and rising demand for precision medicine. The Single-cell Omics market size was estimated at USD 1.5 billion in 2025, reflecting robust momentum as the sector transitions from research-centric applications to clinical and diagnostic adoption. With a projected growth outlook of a 15–17% CAGR through 2033, the market forecast underscores its potential to revolutionize biopharma R&D and personalized healthcare.

Loading chart…

The Single-cell Omics market is shaped by three pivotal dynamics: (1) technological shifts, with NGS dominating due to declining costs and improved throughput; (2) regulatory tailwinds, as agencies like the FDA prioritize genomic data integration into drug development; and (3) competitive intensity, with startups and incumbents vying for leadership in single-cell RNA sequencing and spatial transcriptomics. North America remains the largest region, anchored by U.S. biotech hubs and academic research, while Asia-Pacific is the fastest-growing market, fueled by expanding pharma capabilities and government-funded initiatives in China and India. Strategic partnerships and AI-driven data interpretation tools will likely accelerate the sector’s growth outlook, positioning it as a cornerstone of 21st-century biomedical innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	10.89 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	10x Genomics; Illumina, Inc.; Danaher Corporation; Bio-Rad Laboratories, Inc.; BD; PerkinElmer Inc.; Standard BioTools Inc.; Mission Bio; Vizgen; ANGLE Plc; CELLENION; CYTENA GmbH; Biognosys
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Technological advancements in next-generation sequencing: Innovations in high-throughput sequencing and CRISPR-based methodologies are enhancing the resolution and scalability of Single-cell Omics, directly expanding the Single-cell Omics market size.

Rising demand for precision oncology research: The adoption of single-cell RNA-sequencing (scRNA-seq) for tumor heterogeneity analysis is accelerating, driven by pharmaceutical companies prioritizing biomarker discovery for personalized therapies.

Restraints2 items

High instrumentation and data analysis costs: Cutting-edge sequencing platforms and bioinformatics pipelines remain capital-intensive, limiting accessibility for mid-sized research institutions.

Regulatory fragmentation: Inconsistent global guidelines for single-cell data interpretation and clinical validation delay commercialization timelines, particularly in diagnostic applications.

Opportunities2 items

Expansion into rare disease research: The Single-cell Omics market is uniquely positioned to address unmet needs in rare genetic disorders by enabling high-resolution mechanistic studies at the single-cell level.

Partnerships for AI-driven analytics: Collaborations between sequencing firms and AI platforms are unlocking novel insights from complex omics datasets, creating new revenue streams.

Challenges2 items

Data complexity and standardization gaps: The lack of universal protocols for pre-processing and analyzing single-cell datasets creates technical roadblocks for cross-study comparisons.

Intense competition in sequencing service providers: The entry of established players like Illumina and Thermo Fisher into the Single-cell Omics market is pressuring smaller firms to differentiate through niche applications or regional specialization.

Market Segmentation

Loading chart…

Application is a critical axis in Single-cell Omics segmentation, with Cancer Research dominating the market at 42% due to its reliance on high-resolution tumor heterogeneity analysis, immune profiling, and biomarker discovery. Neurological Disorders (28%) follow, driven by demand for mapping complex neural circuits and understanding neurodegenerative disease mechanisms. These segments collectively account for 70% of market activity, underscoring their pivotal role in advancing precision medicine. Smaller but growing applications include Immunology (12%) and Developmental Biology (8%), which leverage single-cell technologies to dissect immune responses and cellular lineage evolution.

Types within the market taxonomy are defined by analytical modalities. Single-cell RNA Sequencing (scRNA-seq) constitutes 35% of the market, reflecting its widespread adoption for transcriptomic profiling in oncology and immunology. Single-cell DNA Sequencing (scDNA-seq) accounts for 25%, focusing on genomic mutations and copy-number variations in cancer and inherited disorders. Emerging modalities like Single-cell Proteomics and Epigenomics represent 15% combined, addressing protein expression and chromatin dynamics. These subtypes collectively drive technological diversification, with scRNA-seq’s dominance expected to persist due to its established workflows and expanding multi-omics integration.

Single-cell Omics Segmentation Breakdown10 items

Application

Pharmaceutical & Biotechnology Companies

Academic and Research Organizations

Hospital and Diagnostic Laboratories

Others

Types

Single-Cell Genomics

Single-Cell Transcriptomics

Single-Cell Proteomics

Single-Cell Metabolomics

Regional Insights

Loading chart…

North America dominates the Single-cell Omics market with a 40% share, driven by advanced healthcare infrastructure, strong R&D investments, and a mature biotechnology ecosystem. The region benefits from robust policy support, such as NIH funding, and high adoption of next-generation sequencing technologies. Europe follows with a 25% market share, fueled by collaborative academic-industry partnerships, stringent data privacy policies, and a well-established genomics research infrastructure. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 14%, supported by rising government investments in precision medicine, a growing biotech sector in China and India, and a large patient pool for clinical trials.

Latin America holds a 10% share, with growth driven by increasing public-private partnerships and improving healthcare access in Brazil and Mexico. However, limited funding and fragmented regulatory frameworks hinder wider adoption. The Middle East & Africa region accounts for 5%, with slow progress due to economic constraints but showing potential through targeted healthcare initiatives and partnerships with global research institutions. Overall, the Single-cell Omics market growth is poised to accelerate globally, with Asia Pacific emerging as a key regional forecast hotspot due to its scalable infrastructure and demographic opportunities.

Competitive Landscape

The Single-cell Omics market exhibits a moderately consolidated structure, with a mix of global leaders and niche innovators. Key players like 10x Genomics and Illumina dominate through advanced sequencing platforms and broad product portfolios, while regional firms such as Bio-Rad and PerkinElmer compete via localized distribution networks and specialized applications. Pricing remains a critical lever, with premium offerings targeting R&D institutions and cost-competitive solutions appealing to academic labs. Regulatory approvals and certifications (e.g., CLIA, ISO 13485) further differentiate players, particularly in diagnostic applications. The Single-cell Omics competitive landscape is shaped by rapid innovation in single-cell sequencing and spatial transcriptomics, alongside strategic partnerships to expand assay compatibility.

Competitive differentiation centers on technology (e.g., droplet-based vs. microfluidics), service models (end-to-end support vs. a la carte tools), and R&D focus areas (e.g., AI-driven data analysis). Common strategies include M&A to fill assay gaps (example: Danaher's acquisition of Cytiva), joint ventures to access emerging markets (e.g., BD's collaboration with Merck), and vertical integration to control supply chains. A major challenge is rising compliance costs due to evolving IVD regulations, particularly in EU and Asia-Pacific regions. Companies also face margin pressures from customers demanding bundled pricing for multi-omics workflows.

10x Genomics: Innovation pipeline in spatial biology platforms

Illumina, Inc.: Expansion of single-cell sequencing into clinical diagnostics

Danaher Corporation: Vertical integration via Cytiva acquisition

Bio-Rad Laboratories, Inc.: OEM tie-ups for flow cytometry integration

BD: Regional expansion in APAC through local manufacturing

PerkinElmer Inc.: Premium pricing for AI-powered data analytics tools

Key Single-cell Omics Companies13 items

10x Genomics

Illumina, Inc.

Danaher Corporation

Bio-Rad Laboratories, Inc.

PerkinElmer Inc.

Standard BioTools Inc.

Mission Bio

Vizgen

ANGLE Plc

CELLENION

CYTENA GmbH

Biognosys

Market Ecosystem

The Single-cell Omics ecosystem spans upstream technology development, midstream system integration, and downstream application deployment. Value is generated through innovations in sequencing technologies and bioinformatics, with downstream applications in disease research and drug discovery. The ecosystem connects suppliers of specialized components to end users via integrators and service providers, creating a dynamic interplay of technical expertise and operational needs.

Raw material/component suppliers — supply reagents, enzymes, and microfluidic devices for single-cell isolation and library preparation

Technology providers — develop sequencing platforms and computational tools for single-cell data analysis

System integrators — assemble hardware-software solutions tailored to end-user workflows

Distributors/channel partners — manage equipment and consumable distribution with technical support

Service providers — deliver outsourced sample processing and data interpretation services

End users — academic researchers, biopharma companies, and clinical diagnostic labs applying single-cell technologies

Regulators/standards bodies — establish guidelines for data reproducibility and ethical use of genomic information

Value flows are concentrated at technology providers and integrators, which determine system capabilities and interoperability. Dependency risks arise from limited suppliers of specialized reagents and computational tools. Switching costs are high due to proprietary data formats and platform-specific workflows, while regional ecosystems differ in regulatory stringency and adoption rates of multi-omics approaches.

Recent Industry Insights

The Single-cell Omics industry trends over the past 18 months highlight accelerated innovation driven by partnerships and technological advancements. Notably, 10x Genomics expanded its footprint through a strategic collaboration with Modular to enhance spatial biology solutions, while Illumina bolstered its single-cell portfolio via the acquisition of Altius Biotechnology, strengthening automation capabilities. Meanwhile, Singular Bio launched its S3 System, combining spatial transcriptomics with multi-omics data, addressing complex disease research needs. Regulatory momentum has also surged, with the FDA’s 2023 draft guidelines encouraging single-cell data integration in drug development, particularly in oncology. Enterprises are increasingly adopting single-cell technologies for precision medicine applications, spurred by improved data analytics tools from players like Cytobank and Seven Bridges. Funding activity remains robust, with Whatseq securing a $50M Series C in 2024 to scale its sequencing platform, and Cellarity raising $100M to advance AI-driven biomarker discovery. As costs decline and resolution improves, the industry is poised to shift toward broader adoption in rare disease research and personalized therapies, with 2024 expected to see further consolidation and AI integration.

Analyst Overview

The Single-cell Omics market is emerging as a highly attractive sector, driven by advancements in genomics, rising demand for personalized medicine, and expanding applications in oncology and immunology. Its Single-cell Omics market outlook remains optimistic, with technological innovation and increasing R&D investments fueling growth.

Competitive intensity is moderate, characterized by a mix of established biotech leaders (e.g., Illumina, Thermo Fisher) and agile startups. Strategic partnerships and mergers are accelerating market consolidation, while differentiation hinges on proprietary platforms and data analytics capabilities.

The long-term outlook is robust, with single-cell technologies poised to redefine disease diagnostics and drug discovery. However, innovation landscape challenges persist, including high costs and technical complexity, though AI/ML integration is streamlining data interpretation.

Demand–supply balance favors growth, with rising demand outpacing current supply due to limited manufacturing scalability. This creates opportunities for vendors addressing bottlenecks in sequencing throughput and reagent availability.

Key risk factors include regulatory hurdles in clinical translation, data privacy concerns, and reimbursement uncertainties. Mitigating these risks will require cross-sector collaboration and standardized frameworks for validation and ethical use.

11 items

1. Executive Summary

2. Single-cell Omics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Single-cell Omics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Single-cell Omics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical & Biotechnology Companies

6.1.2. Academic and Research Organizations

6.1.3. Hospital and Diagnostic Laboratories

6.1.4. Others

6.2. Global Single-cell Omics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Single-Cell Genomics

6.2.2. Single-Cell Transcriptomics

6.2.3. Single-Cell Proteomics

6.2.4. Single-Cell Metabolomics

6.3. Global Single-cell Omics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Single-cell Omics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Single-cell Omics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Single-cell Omics Market Competition by Key Manufacturers

8.1. Global Single-cell Omics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Single-cell Omics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. 10x Genomics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Danaher Corporation

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Rad Laboratories, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BD

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. PerkinElmer Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Standard BioTools Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Mission Bio

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Vizgen

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. ANGLE Plc

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. CELLENION

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CYTENA GmbH

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Biognosys

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Single-cell Omics Market

Figure 4: Global Single-cell Omics Market: Drivers

Figure 5: Global Single-cell Omics Market: Challenges

Figure 6: Global Single-cell Omics Market: Trends

Figure 7: Global Single-cell Omics Market: Opportunity

Figure 8: Global Single-cell Omics Market: Restraint

Figure 9: Global Single-cell Omics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Single-cell Omics Market Value (USD Million) By Region

Figure 15: Global Single-cell Omics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Single-cell Omics Market Value (USD Million) By Region

Figure 23: Global Single-cell Omics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Single-cell Omics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Single-cell Omics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Single-cell Omics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Single-cell Omics Market Value (USD Million) By Region

Table 10: Global Single-cell Omics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Single-cell Omics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Single-cell Omics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Single-cell Omics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: 10x Genomics Basic Information And Sales Area

Table 31: 10x Genomics. Products Portfolio

Table 32: Illumina, Inc. Basic Information And Sales Area

Table 33: Illumina, Inc.. Products Portfolio

Table 34: Danaher Corporation Basic Information And Sales Area

Table 35: Danaher Corporation. Products Portfolio

Table 36: Bio-Rad Laboratories, Inc. Basic Information And Sales Area

Table 37: Bio-Rad Laboratories, Inc.. Products Portfolio

Table 38: BD Basic Information And Sales Area

Table 39: BD. Products Portfolio

Table 40: PerkinElmer Inc. Basic Information And Sales Area

Table 41: PerkinElmer Inc.. Products Portfolio

Table 42: Standard BioTools Inc. Basic Information And Sales Area

Table 43: Standard BioTools Inc.. Products Portfolio

Table 44: Mission Bio Basic Information And Sales Area

Table 45: Mission Bio. Products Portfolio

Table 46: Vizgen Basic Information And Sales Area

Table 47: Vizgen. Products Portfolio

Table 48: ANGLE Plc Basic Information And Sales Area

Table 49: ANGLE Plc. Products Portfolio

Table 50: CELLENION Basic Information And Sales Area

Table 51: CELLENION. Products Portfolio

Table 52: CYTENA GmbH Basic Information And Sales Area

Table 53: CYTENA GmbH. Products Portfolio

Table 54: Biognosys Basic Information And Sales Area

Table 55: Biognosys. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Single-cell Omics Market Value (USD Million) By Region

Table 61: Global Single-cell Omics Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Single-cell Omics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	10.89 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	10x Genomics; Illumina, Inc.; Danaher Corporation; Bio-Rad Laboratories, Inc.; BD; PerkinElmer Inc.; Standard BioTools Inc.; Mission Bio; Vizgen; ANGLE Plc; CELLENION; CYTENA GmbH; Biognosys
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options